Critical thinking: An essential role in both the conduct and interpretation of gynecologic cancer clinical research

Gynecologic Oncology

Volumn 108, Issue 3, 2008, Pages 462-465

  Markman, Maurie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PLATINUM;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CRITICAL THINKING; CURRICULUM DEVELOPMENT; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; DRUG MEGADOSE; EDITORIAL; GYNECOLOGIC CANCER; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HUMAN; MEDICAL EDUCATION; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUMOR VOLUME;

EID: 39449115413     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.10.006     Document Type: Editorial

References (24)

1. Croskerry P. Critical thinking and decision making: avoiding the perils of thin-slicing. Ann Emerg Med 48 6 (2006) 720-722
2. Brody H. Hooked: ethics, the medical profession and the pharmaceutical industry (2007), Lanham, Rowman & Littlefield Publishers, Inc
3. Markman M. Cytotoxic intracavitary chemotherapy. Am J Med Sci 291 3 (1986) 175-179
4. Markman M. Intraperitoneal chemotherapy as treatment of ovarian carcinoma: why, how, and when?. Obstet Gynecol Surv 42 9 (1987) 533-539
5. Durant R.E. Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro. Cancer Res 41 (1981) 3495-3498
6. Ozols R.F., Locker G.Y., Doroshow J.H., Grotzinger K.R., Myers C.E., and Young R.C. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 39 8 (1979) 3209-3214
7. West G.W., Weichselbau R., and Little J.B. Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res 40 (1980) 3665-3668
8. Nederman T., and Carlsson J. Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids. Cancer Chemother Pharmacol 13 (1984) 131-135
9. Los G., Mutsaers P.H.A., van der Vijgh W.J.F., Baldew G.S., de Graaf P.W., and McVie J.G. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 49 (1989) 3380-3384
10. Markman M., Reichman B., Hakes T., Jones W., Lewis Jr. J.L., Rubin S., et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 9 10 (1991) 1801-1805
11. Shapiro F., Schneider J., Markman M., Reichman B.S., Venkatraman E., Barakat R., et al. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up. Gynecol Oncol 67 1 (1997) 39-45
12. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19 4 (2001) 1001-1007
13. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335 26 (1996) 1950-1955
14. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 1 (2006) 34-43
15. Howell S.B., Pfeifle C.E., Wung W.E., and Olshen R.A. Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 43 3 (1983) 1426-1431
16. Casper E.S., Kelsen D.P., Alcock N.W., and Lewis Jr. J.L. Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the IV route. Cancer Treat Rep 67 3 (1983) 235-238
17. Lopez J.A., Krikorian J.G., Reich S.D., Smyth R.D., Lee F.H., and Issell BF. Clinical pharmacology of intraperitoneal cisplatin. Gynecol Oncol 20 1 (1985) 1-9
18. Pretorius R.G., Hacker N.F., Berek J.S., Ford L.C., Hoeschele J.D., Butler TA., et al. Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. Cancer Treat Rep 67 12 (1983) 1085-1092
19. Covens A., Carey M., Bryson P., Verma S., Fung Kee F.M., and Johnston M. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 85 1 (2002) 71-80
20. Markman M. The dangers of "cross-trial" and "cross-retrospective experience" comparisons: examples employing data in the peer-reviewed ovarian cancer literature. Cancer 109 10 (2007) 1929-1932
21. Markman M. Use of positron emission tomography scans in ovarian cancer: a diagnostic technique in search of an indication. J Clin Oncol 23 30 (2005) 7385-7387
22. Markman M. The objectivity of reports describing the use of novel diagnostic tests in the management of ovarian cancer: a critique. Gynecol Oncol 104 2 (2007) 271-272
23. Farquhar C, Marjoribanks J, Basser R, Hetrick S, Lethaby A. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer (Review). Cochrane Database of Systemic Reviews 2005; Issue 3, Art. No.: CD003142. doi:10.1002/14651858.CD003142.pub2.
24. Grenman S., Wiklund T., Jalkanen J., Kuoppala T., Maenpaa J., Kuronen A., et al. A randomized phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: the Finnish Ovarian Cancer (FINOVA) study. Eur J Cancer 42 (2006) 2196-2199